WO2001082933A3 - Compositions and methods for stabilizing modified tissue - Google Patents

Compositions and methods for stabilizing modified tissue Download PDF

Info

Publication number
WO2001082933A3
WO2001082933A3 PCT/US2001/012127 US0112127W WO0182933A3 WO 2001082933 A3 WO2001082933 A3 WO 2001082933A3 US 0112127 W US0112127 W US 0112127W WO 0182933 A3 WO0182933 A3 WO 0182933A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tissue
methods
modification
modified tissue
Prior art date
Application number
PCT/US2001/012127
Other languages
French (fr)
Other versions
WO2001082933A2 (en
Inventor
Ali Zendedel Haghighi
Original Assignee
Sunrise Technologies Internati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunrise Technologies Internati filed Critical Sunrise Technologies Internati
Priority to AU2001253469A priority Critical patent/AU2001253469A1/en
Publication of WO2001082933A2 publication Critical patent/WO2001082933A2/en
Publication of WO2001082933A3 publication Critical patent/WO2001082933A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods for stabilizing modified tissue, particularly against post-modification regression, are provided. More particularly, pre-treatment and post-treatment compositions are applied to tissue that is subjected to a modification procedure. The compositions condition the tissue to resist regression toward its original, pre-modification state. The invention is applicable to collagenous tissue throughout the body, and particularly applicable to corneal tissue that is subjected to a refractive-correction procedure, such as laser thermal keratoplasty.
PCT/US2001/012127 2000-04-27 2001-04-13 Compositions and methods for stabilizing modified tissue WO2001082933A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001253469A AU2001253469A1 (en) 2000-04-27 2001-04-13 Compositions and methods for stabilizing modified tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55993300A 2000-04-27 2000-04-27
US09/559,933 2000-04-27

Publications (2)

Publication Number Publication Date
WO2001082933A2 WO2001082933A2 (en) 2001-11-08
WO2001082933A3 true WO2001082933A3 (en) 2002-07-18

Family

ID=24235662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012127 WO2001082933A2 (en) 2000-04-27 2001-04-13 Compositions and methods for stabilizing modified tissue

Country Status (2)

Country Link
AU (1) AU2001253469A1 (en)
WO (1) WO2001082933A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
WO2013148895A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2013149075A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010809A1 (en) * 1991-11-27 1993-06-10 New York Blood Center, Inc. Fibronectin-containing ophthalmic solution, method of manufacture of an ophthalmic solution, method of preserving an ophthalmic solution, and methods of treatment of ophthalmic wounds
WO1993015234A1 (en) * 1992-01-22 1993-08-05 Novo Nordisk A/S Activated factor xiii
EP0628314A1 (en) * 1993-06-04 1994-12-14 Senju Pharmaceutical Co., Ltd. Ophthalmic topical composition containing glucose for inhibiting injury to the corneal endothelium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010809A1 (en) * 1991-11-27 1993-06-10 New York Blood Center, Inc. Fibronectin-containing ophthalmic solution, method of manufacture of an ophthalmic solution, method of preserving an ophthalmic solution, and methods of treatment of ophthalmic wounds
WO1993015234A1 (en) * 1992-01-22 1993-08-05 Novo Nordisk A/S Activated factor xiii
EP0628314A1 (en) * 1993-06-04 1994-12-14 Senju Pharmaceutical Co., Ltd. Ophthalmic topical composition containing glucose for inhibiting injury to the corneal endothelium

Also Published As

Publication number Publication date
WO2001082933A2 (en) 2001-11-08
AU2001253469A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
BR0209439B1 (en) chapel lock mechanism for an explosion preventive controller, explosion preventive controller and method for attaching a chapel to a body of an explosion preventive controller.
WO2007030574A3 (en) 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
WO2006138046A3 (en) Method and apparatus to facilitate handover
WO2004098494A3 (en) Compounds, compositions, and methods
BR0114054A (en) Method to Treat Allergies Using Substituted Pyrazoles
WO2000013266A3 (en) A diode-pumped cascade laser for deep uv generation
EP2397107A3 (en) Surgical scaffold
EP1475080A3 (en) Cosmetic composition for the treatment of skin ageing and/or stressed skin
DK1818059T3 (en) Preventive or therapeutic agent for glaucoma
BR0017157A (en) 6-hydroxy-indazole derivatives for the treatment of glaucoma
ATE273694T1 (en) TEAR SUBSTITUTES
WO2008058671A3 (en) Projection apparatus having improved projection properties
DE602006010714D1 (en) Ring anastomosis with closure agent
WO2003015725A3 (en) Compositions comprising at least one hydroxide compound and at least one reducing agent, and methods for relaxing hair
WO2001082933A3 (en) Compositions and methods for stabilizing modified tissue
WO2004052313A3 (en) Anti-infectives
WO2004058150A3 (en) Anti-infectives
AR026708A1 (en) DERIVATIVES OF 5-HYDROXY-INDAZOL FOR THE TREATMENT OF GLAUCOMA
WO2002034233A3 (en) Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing
WO2003051299A3 (en) Sulfhydryl rifamycins and uses thereof
BR0015630B1 (en) insulating refractory material, article, and, aqueous composition for the manufacture of an insulating refractory material.
WO2002074193A3 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
WO2003059265A3 (en) Compositions and methods for treating heart failure
BR0213179A (en) Methods for treating dry eyes by a combination of an anti-inflammatory steroid and a muc-1 secretagogue
WO2006116374A3 (en) Surface treatments for promoting selective tissue attachment to medical implants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP